-
1
-
-
84863911486
-
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV nonsmall-cell lung cancer: Results from a randomized, doubleblind, multicenter phase II study
-
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV nonsmall-cell lung cancer: results from a randomized, doubleblind, multicenter phase II study. J Clin Oncol 2012;30:2046-54.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2046-2054
-
-
Lynch, T.J.1
Bondarenko, I.2
Luft, A.3
Serwatowski, P.4
Barlesi, F.5
Chacko, R.6
-
2
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR., Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
3
-
-
84890927236
-
Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): Overall survival and long-term safety in a phase 1 trial
-
Oct. 27-30; Sydney, Australia MO18.03
-
Brahmer JR, Horn L, Antonia SJ, Spigel D, Ghandi L, Sequist LV, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. In: IASLC15th World Conference on Lung Cancer; 2013 Oct. 27-30; Sydney, Australia MO18.03.
-
(2013)
IASLC15th World Conference on Lung Cancer
-
-
Brahmer, J.R.1
Horn, L.2
Antonia, S.J.3
Spigel, D.4
Ghandi, L.5
Sequist, L.V.6
-
4
-
-
84890898377
-
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with ndn-small cell lung cancer (NSCLC) treated with nivolumab (ANTI-PD-1; BMS-936558; ONO-4538)
-
Oct. 27-30; Sydney, Australia
-
Antonia SJ, Grosso JF, Horak CE, Harbison CT, Kurland JF, Inzunza HD, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with ndn-small cell lung cancer (NSCLC) treated with nivolumab (ANTI-PD-1; BMS-936558; ONO-4538). In: IASLC 15th World Conference on Lung Cancer; 2013 Oct. 27-30; Sydney, Australia P2.11-035.
-
(2013)
IASLC 15th World Conference on Lung Cancer
, pp. P211-P1035
-
-
Antonia, S.J.1
Grosso, J.F.2
Horak, C.E.3
Harbison, C.T.4
Kurland, J.F.5
Inzunza, H.D.6
-
5
-
-
84890931891
-
Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC)
-
Oct. 27-30; Sydney, Australia MO 18.02
-
Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighl N. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). In: IASLC 15th World Conference on Lung Cancer; 2013 Oct. 27-30; Sydney, Australia MO 18.02.
-
(2013)
IASLC 15th World Conference on Lung Cancer
-
-
Garon, E.B.1
Balmanoukian, A.2
Hamid, O.3
Hui, R.4
Gandhi, L.5
Leighl, N.6
-
6
-
-
84880709088
-
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
-
8008
-
Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2013;31(Suppl):Abstr 8008.
-
(2013)
J Clin Oncol
, vol.31
-
-
Spigel, D.R.1
Gettinger, S.N.2
Horn, L.3
Herbst, R.S.4
Gandhi, L.5
Gordon, M.S.6
-
7
-
-
84908385550
-
An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients wim non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1)
-
Jul. 2-5; Amsterdam, the Netherlands, MO 18.01
-
Horn L, Herbst RS, Spiegel D, Gettinger SN, Gordon MS, Hollebecque A, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients wim non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). In: IASLC 14th World Conference on Lung Cancer; 2011 Jul. 2-5; Amsterdam, the Netherlands. MO 18.01.
-
(2011)
IASLC 14th World Conference on Lung Cancer
-
-
Horn, L.1
Herbst, R.S.2
Spiegel, D.3
Gettinger, S.N.4
Gordon, M.S.5
Hollebecque, A.6
-
8
-
-
84862903106
-
Safety and activity of anti-PD-Ll antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-Ll antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
9
-
-
84890893426
-
MEDI4736, an anti-PD-Ll antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase I study in patients with advanced solid tumors
-
802 Sep. 27-Oct. 1; Amsterdam, The Netherlands
-
Khleif SN, Lutzky J, Segal NH, Antonia S, Blake-Haskins A, Stewart R, et al. MEDI4736, an anti-PD-Ll antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase I study in patients with advanced solid tumors. In: Proceedings from die European Cancer Congress 2013; 2013 Sep. 27-Oct. 1; Amsterdam, The Netherlands. Abstract No. 802.
-
(2013)
Proceedings from die European Cancer Congress 2013
-
-
Khleif, S.N.1
Lutzky, J.2
Segal, N.H.3
Antonia, S.4
Blake-Haskins, A.5
Stewart, R.6
-
10
-
-
84880755387
-
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results
-
Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31:2396-403.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2396-2403
-
-
Vansteenkiste, J.1
Zielinski, M.2
Linder, A.3
Dahabreh, J.4
Gonzalez, E.E.5
Malinowski, W.6
-
11
-
-
84880720167
-
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy
-
Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2388-2395
-
-
Ulloa-Montoya, F.1
Louahed, J.2
Dizier, B.3
Gruselle, O.4
Spiessens, B.5
Lehmann, F.F.6
-
12
-
-
80054742888
-
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial
-
Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137:1337-42.
-
(2011)
J Cancer Res Clin Oncol
, vol.137
, pp. 1337-1342
-
-
Butts, C.1
Maksymiuk, A.2
Goss, G.3
Soulieres, D.4
Marshall, E.5
Cormier, Y.6
-
13
-
-
84891373760
-
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial
-
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
-
(2014)
Lancet Oncol
, vol.15
, pp. 59-68
-
-
Butts, C.1
Socinski, M.A.2
Mitchell, P.L.3
Thatcher, N.4
Havel, L.5
Krzakowski, M.6
-
14
-
-
33750586798
-
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense genemodified allogeneic tumor cell vaccine in non-small-cell lung cancer
-
Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cuder J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense genemodified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-30.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4721-4730
-
-
Nemunaitis, J.1
Dillman, R.O.2
Schwarzenberger, P.O.3
Senzer, N.4
Cunningham, C.5
Cuder, J.6
-
15
-
-
67651091694
-
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
-
Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009;16:620-4.
-
(2009)
Cancer Gene Ther
, vol.16
, pp. 620-624
-
-
Nemunaitis, J.1
Nemunaitis, M.2
Senzer, N.3
Snitz, P.4
Bedell, C.5
Kumar, P.6
|